The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nautilus, a phase 1b/2 trial of combining oral HDAC inhibitor (HDACi) with MEK inhibitor (MEKi) in patients with NRAS-mutated metastatic melanoma (MM).
 
Rodabe Amaria
Consulting or Advisory Role - Erasca, Inc; IO Biotech; KSQ Therapeutics; Obsidian Therapeutics; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Erasc (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); KSQ Therapeutics (Inst); Novartis (Inst); Obsidian Therapeutics (Inst); OnKure (Inst); Regeneron (Inst)
 
Herbert Duvivier
Speakers' Bureau - AstraZeneca; Guardant Health; Regeneron
 
Katy Tsai
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene
Research Funding - ABM (Inst); AstraZeneca (Inst); BioAtla (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Georgiamune (Inst); IDEAYA Biosciences (Inst); Innovent Biologics (Inst); Merck (Inst); Oncosec (Inst); OnKure (Inst); Pfizer (Inst); Replimune (Inst)
 
Parisa Momtaz
No Relationships to Disclose
 
Robert Galamaga
Research Funding - OnKure (Inst)
 
Evan Pisick
No Relationships to Disclose
 
Bently Doonan
Honoraria - Curis
Consulting or Advisory Role - Curis; Immunocore; Pfizer; Replimune
Research Funding - Curis; Merck; Regeneron (Inst)
 
Amy Weise
Employment - N/A
Leadership - N/A
Stock and Other Ownership Interests - N/A
Honoraria - N/A
Consulting or Advisory Role - N/A
Speakers' Bureau - N/A
Research Funding - N/A
Patents, Royalties, Other Intellectual Property - N/A
Expert Testimony - N/A
Travel, Accommodations, Expenses - N/A
Other Relationship - N/A
 
Natalie Langr
Employment - OnKure
Stock and Other Ownership Interests - OnKure
Travel, Accommodations, Expenses - OnKure
 
James Winkler
Employment - OnKure
Stock and Other Ownership Interests - OnKure
 
Harish Dave
Employment - AUM Biosciences
Leadership - AUM Biosciences
Stock and Other Ownership Interests - AUM Biosciences
 
Jennifer Diamond
Leadership - OnKure (Inst)
Stock and Other Ownership Interests - OnKure
Consulting or Advisory Role - Gilead Sciences (Inst)
Research Funding - Adlai Nortye (Inst); AstraZeneca/UK (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cosmo Pharmaceuticals (Inst); Decipher Biosciences (Inst); Gilead Sciences (Inst); Merck Sharp & Dohme (Inst); OnKure (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - OnKure
 
Ryan Sullivan
Consulting or Advisory Role - BridGene Biosciences; Bristol-Myers Squibb; Marengo Therapeutics; Merck; Novartis; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Georgimmune (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)